IPHA Innate Pharma SA IFRS Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1598599 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 9.01M | 20.12M | 61.64M | 57.67M | 24.70M |
| R&D expense | 43.62M | 51.98M | 56.02M | 51.66M | 47.00M |
| SG&A expense | 19.39M | 19.72M | 18.29M | 22.44M | 25.52M |
| Operating income | -54.01M | -51.58M | -12.67M | -57.42M | -47.83M |
| Interest expense | 440,000 | 566,000 | 640,000 | 288,000 | 312,000 |
| Pretax income | -49.18M | -49.47M | -7.57M | -57.97M | -45.48M |
| Income tax | 0 | 0 | 0 | 0 | 0 |
| Net income | -49.18M | -49.47M | -7.57M | -58.10M | -52.81M |
| EBITDA | -52.62M | -49.59M | -7.58M | -53.00M | -43.26M |
| EPS (basic) | -0.55 | -0.61 | -0.09 | -0.73 | -0.66 |
| EPS (diluted) | -0.55 | -0.61 | -0.09 | -0.73 | -0.66 |
| Balance sheet | |||||
| Cash & equivalents | 28.09M | 66.40M | 70.61M | 84.22M | 103.76M |
| Short-term investments | 6.22M | 14.38M | 21.85M | 17.26M | 16.08M |
| Receivables | 12.40M | 4.97M | 55.56M | 38.35M | 18.42M |
| Current assets | 46.71M | 85.74M | 148.01M | 139.83M | 138.26M |
| PP&E, netmay include right-of-use assets (IFRS) | 4.36M | 5.13M | 6.32M | 8.54M | 10.17M |
| Intangibles | 0 | 0 | 416,000 | 1.55M | 44.19M |
| Total assets | 62.72M | 111.06M | 175.19M | 199.29M | 267.50M |
| Current liabilities | 36.65M | 32.98M | 39.64M | 41.34M | 79.89M |
| Total liabilities | 84.42M | 102.22M | 123.29M | 145.14M | 160.06M |
| Shareholders' equity | -21.70M | 8.83M | 51.90M | 54.15M | 107.44M |
| Shares outstanding | — | — | — | 79.54M | — |
| Cash flow statement | |||||
| Operating cash flow | -52.76M | -6.90M | -32.56M | -19.16M | -58.46M |
| Capital expenditure | 140,000 | 391,000 | 351,000 | 535,000 | 929,000 |
| Free cash flow | -52.90M | -7.29M | -32.91M | -19.69M | -59.39M |
| Investing cash flow | 7.29M | 9.20M | 20.63M | 1.88M | -917,000 |
| Financing cash flow | 6.07M | -6.01M | -1.97M | -1.83M | 26.82M |
| Depreciation & amortization | 1.38M | 1.99M | 5.09M | 4.42M | 4.57M |
| Stock-based compensation | 2.57M | 3.94M | 4.26M | 4.25M | 2.62M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.